Insights into Structure-Activity Relationships of Somatostatin Analogs Containing Mesitylalanine. by Martín-Gago, Pablo et al.
 Molecules 2013, 18, 14564-14584; doi:10.3390/molecules181214564 
 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Article 
Insights into Structure-Activity Relationships of Somatostatin 
Analogs Containing Mesitylalanine 
Pablo Martín-Gago 1, Eric Aragón 1, Marc Gomez-Caminals 2, Jimena Fernández-Carneado 2, 
Rosario Ramón 1,3, Pau Martin-Malpartida 1, Xavier Verdaguer 1,3, Pilar López-Ruiz 4,  
Begoña Colás 4, María Alicia Cortes 4, Berta Ponsati 2, Maria J. Macias 1,5,* and Antoni Riera 1,3,* 
1 Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; 
E-Mails: pablo.martin@irbbarcelona.org (P.M.-G.); eric.aragon@irbbarcelona.org (E.A.);  
rosario.ramon.albalate@gmail.com (R.R.); pau.martin@irbbarcelona.org (P.M.-M.); 
xavier.verdaguer@irbbarcelona.org (X.V.) 
2 BCN Peptides S.A. Pol.Ind. Els Vinyets-Els Fogars, Sector II. Ctra. Comarcal 244, Km. 22, 08777 
Sant Quintí de Mediona, Barcelona 08777, Spain; E-Mails: mgomez@bcnpeptides.com (M.G.-C.);  
jfernandez@bcnpeptides.com (J.F.-C.); bponsati@bcnpeptides.com (B.P.) 
3 Departament de Química Orgànica, Universitat de Barcelona, Martí i Franqués, 1-11,  
Barcelona 08028, Spain 
4 Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá de Henares,  
Facultad de Medicina, Madrid 28871, Spain; E-Mails: pilar.lopezruiz@uah.es (P.L.-R.);  
begona.colas@uah.es (B.C.); alicia.cortes@uah.es (M.A.C.) 
5 Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluis Companys, 23, 
Barcelona 08010, Spain 
* Authors to whom correspondence should be addressed;  
E-Mails: maria.macias@irbbarcelona.org (M.J.M.); antoni.riera@irbbarcelona.org (A.R.);  
Tel.: +34-934-037-189 (M.J.M.); Fax: +34-934-047-095 (M.J.M.);  
Tel. +34-934-047-093 (A.R.); Fax: +34-934-047-095 (A.R). 
Received: 30 October 2013; in revised form: 12 November 2013 / Accepted: 13 November 2013 /  
Published: 25 November 2013 
 
Abstract: The non-natural amino acid mesitylalanine (2,4,6-trimethyl-L-phenylalanine; 
Msa) has an electron-richer and a more conformationally restricted side-chain than that of 
its natural phenylalanine counterpart. Taking these properties into account, we have 
synthesized ten somatostatin analogs containing Msa residues in different key positions to 
modify the intrinsic conformational flexibility of the natural hormone. We have measured 
the binding affinity of these analogs and correlated it with the main conformations they 
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populate in solution. NMR and computational analysis revealed that analogs containing 
one Msa residue were conformationally more restricted than somatostatin under similar 
experimental conditions. Furthermore, we were able to characterize the presence of a 
hairpin at the pharmacophore region and a non-covalent interaction between aromatic 
residues 6 and 11. In all cases, the inclusion of a D-Trp in the eighth position further 
stabilized the main conformation. Some of these peptides bound selectively to one or two 
somatostatin receptors with similar or even higher affinity than the natural hormone. 
However, we also found that multiple incorporations of Msa residues increased the life 
span of the peptides in serum but with a loss of conformational rigidity and binding affinity. 
Keywords: somatostatin; drug design; peptidic hormones; non-covalent interactions; 
NMR; structure-activity relationships; conformational analysis 
 
1. Introduction 
1.1. Somatostatin Analogs 
Site directed mutagenesis is a well-established method to modify the properties of proteins and 
peptides. These modifications normally include changes in hydrophobicity, stability, conformation and 
biological activity of the new molecules [1–4]. Somatostatin [5,6], also known as somatotropin 
release-inhibiting factor (SRIF-14) (Figure 1), is one of the most studied peptides due to its important 
biological properties. This hormone is produced in the hypothalamus and is involved in multiple 
biological functions, mediated by its direct interaction with at least five different G-protein coupled 
receptors, named SSTR1-5 [7,8]. The use of this hormone in several different clinical treatments  
(anti-secretory drug, growth hormone secretion disorders and endocrine tumor treatment) [9–12] 
reflects its pharmacological importance. However, its short half-life (2–3 min in plasma in vivo) and its 
low selectivity (high binding affinity towards all five different receptors) are the major disadvantages 
of natural SRIF as a drug. 
Figure 1. Amino acid sequence of somatostatin. 
 
A myriad of SRIF analogs have been synthesized over the past few decades introducing 
modifications such as exchange and deletion of amino acids, ring size reduction, disulfide bridge 
modification, multiple N-methylation and site-specific PEGylation [13–16]. Several of those analogs 
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displayed an improvement of different “drug-like” properties in comparison to somatostatin. A few 
synthetic analogs have reached the market: octreotide (Sandostatin®) [17,18] lanreotide (Somatuline®), 
vapreotide (Sanvar®) and pasireotide (Signifor®) [19] (Figure 2). These are octa- or hexapeptides, thus 
having a shorter and consequently less flexible ring than that of somatostatin. They are long-acting 
analogs with increased plasma stability and are highly selective against receptor SSTR2. To date, most 
of the research efforts in this field have focused on the design of new more conformationally restricted 
analogs with shorter rings (octreotide analogs, in fact), and on the improvement of the methodology to 
prepare them in an efficient and simple manner. The current solid-phase protocols have diminished the 
challenge of obtaining 14-residue’s peptides, and thus, our approach to prepare new analogs is based 
on synthesizing full-length SRIF-14 analogs with particular site-directed modifications [20,21]. Our 
aim is to improve the stability and receptor selectivity of natural somatostatin and to overcome the 
main drawback of octapeptide derivatives, which is the loss of activity in certain receptors. 
Figure 2. Amino acid sequences of the marketed short-ring analogs. 
 
1.2. Somatostatin Structure 
The structure of somatostatin in solution shows a high conformational flexibility [22–25] and its 
native structure is now considered as an ensemble of several interchanging conformations in 
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equilibrium [26]. Despite three decades of work in this field, it has not been possible to determine the 
specific conformation of SRIF that is recognized by each receptor subtype. Nevertheless, the synthesis 
of shorter ring analogs in the last years has afforded numerous compounds with different receptor 
selectivity. Their smaller size and reduced mobility has allowed the structural characterization of some 
of these analogs [13,27–31]. However, these structures cannot provide an accurate picture of the 
different bioactive conformations of SRIF, due to significant differences in sequence and function 
between SRIF and the published octapeptide analogs. 
Several studies have been devoted to determining the role of the different residues in the natural 
hormone sequence [32]. It is well accepted that the four amino acid sequence Phe7-Trp8-Lys9-Thr10 
constitutes the pharmacophore. Small modifications of these four residues can be made without a 
significant loss of activity. Examination of the three marketed analogs reveals that all have a similar 
four residue fragment: Lys9 is always conserved; Trp8 has been replaced by its enantiomer, and Thr  
by Val. In all cases Phe6 and Phe11 have been replaced by cysteine as a surrogate of the putative 
Phe6-Phe11 aromatic interaction. 
Early studies [33] uncovered the possibility that an aromatic interaction between Phe6 and Phe11 
could play a key role in the structural stabilization of the hormone (Figure 3). This hypothesis was 
supported by pioneering NMR experiments carried out by Arison et al. [34]. The temperature 
dependence in the chemical shift showed that the Phe6 protons where in the shielding cone of an 
aromatic ring. NMR studies of both SRIF and a shorter analogue carried out by Cutnell et al. [35] 
provided geometric information about this non-covalent interaction. The temperature effect on the 
Phe6 protons shifts was not consistent with parallel stacking, so a perpendicular aromatic interaction 
was proposed (with o- and m-H of Phe6 pointing near the center of a second aromatic ring). The 
authors also showed that replacement of Phe7 by Ala in this smaller analogue retained the up-field  
o-H resonance of Phe6, whilst Phe11 substitution with Ala completely eliminates this shift. This 
observation confirmed the hypothesis that Phe11 is shielding the aromatic ring of Phe6 in this 
“perpendicular” aromatic interaction, and this interaction is also present in the active conformations of 
the natural counterpart. However, other authors have re-examined this issue and, no NOE’s between 
Phe11 and any of the other aromatic rings were detected using 2D NOESY 1H-NMR studies [36,37]. 
Van Binst and co-workers concluded from this that the Phe6-Phe11 interaction proposed by  
Veber et al. was not significantly present in the main conformations of SRIF in aqueous solution. 
Figure 3. Proposed Phe6-Phe11 aromatic stabilizing interaction. 
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1.3. Somatostatin Analogs with Mesitylalanine 
Exploring the putative aromatic-aromatic interactions that stabilize some bioactive conformations in 
SRIF seemed to be a very straightforward way to generate analogs with enhanced stability, 
conformational rigidity and different biological activity. The present knowledge about aromatic  
side-chain interactions, together with the increased interest in the structure-activity relationships, 
prompted us to exploit the effect of such interactions in new SRIF analogs. As a part of an ongoing 
study of 14-amino acid SRIF analogs, we decided to incorporate mesitylalanine residues with  
higher electron density than phenylalanines, and with the intrinsic rigidity provided by the ortho 
substitution [38]. To this end, we synthetized ten peptides containing Msa; four of them were 
previously described [21], but are included here for completeness (Table 1). 
Table 1. Somatostatin analogs obtained by replacement of the Phe in positions 6, 7 and/or 
11 by mesitylalanine (Msa). In compounds 4–6 the natural Trp in position 8 was replaced 
by D-Trp. 
 
Entry Xa(6) Xb(7) Xc(8) Xd(11) Peptide analog 
1 Msa Phe L-Trp Phe [L-Msa6]-SRIF, 1 
2 Phe Msa L-Trp Phe [L-Msa7]-SRIF, 2 a 
3 Phe Phe L-Trp Msa [L-Msa11]-SRIF, 3 
4 Msa Phe D-Trp Phe [L-Msa6,D-Trp8]-SRIF, 4 a 
5 Phe Msa D-Trp Phe [L-Msa7,D-Trp8]-SRIF, 5 a 
6 Phe Phe D-Trp Msa [L-Msa11,D-Trp8]-SRIF, 6 a 
7 Msa Msa L-Trp Phe [L-Msa6,7]-SRIF, 7 
8 Msa Phe L-Trp Msa [L-Msa6,11]-SRIF, 8 
9 Phe Msa L-Trp Msa [L-Msa7,11]-SRIF, 9 
10 Msa Msa L-Trp Msa [L-Msa6,7,11]-SRIF, 10 
a Described in the preliminary communication [21]. 
The first group of compounds 1–3 were obtained by the replacement of each of the three 
phenylalanine residues on the natural 14-amino acid sequence (positions 6, 7 and 11) with Msa. Since 
it is known that exchanging L-Trp with its enantiomer does not significantly change the activity profile 
and increases the stability of the molecule [39–41] a second group of peptides with D-Trp in position 
eight was prepared (compounds 4–6). Two replacements of phenylalanine residues with Msa afforded 
three more peptides 7–9. Finally, the replacement of all three phenylalanine residues with Msa 
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afforded peptide 10. Fmoc-L-3-mesitylalanine was obtained either following the procedure previously 
developed by our group [42] or by enantioselective hydrogenation [43,44]. 
2. Results and Discussion 
2.1. Synthesis of Tetradecapeptides with Mesitylalanine 
Peptide analogs 1–10 (Table 1) were prepared by solid-phase peptide synthesis (SPPS) on 2-chlorotrityl 
chloride resin, using the Fmoc/tBu strategy. The coupling of the first amino acid Fmoc-Cys(Trt)-OH 
was performed in dichloromethane (DCM) in the presence of N-ethyldiisopropylamine (DIPEA). After the 
coupling was finished, the remaining free chlorides were capped with methanol. The next Fmoc-protected 
amino acids (and the last Boc-Ala-OH) were added using N,N’-diisopropylcarbodiimide (DIC) and  
1-hydroxybenzotriazole (HOBt) in DMF. Piperidine in DMF (20%) was used to remove the Fmoc 
protecting group. When the non-natural amino acid was incorporated, only 1.5 equiv were used in the 
coupling. The formation of the disulfide bridge was achieved in solution at room temperature with 
iodine (I2), after cleavage (DCM/TFE/AcOH) of the fully protected linear peptide from the resin. 
Finally, side chain deprotection using a mixture of TFA/DCM/anisole/H2O for 4 h afforded SRIF-14 
analogs in modest yields (20%–50%) and moderate purities that were improved up to 99% by  
HPLC chromatography. 
2.2. Serum Stability 
The low stability of natural SRIF (with a half-life of 2–3 min in vivo in human plasma) is one of the 
main drawbacks of its pharmaceutical use. Thus, we were interested in determining whether our new 
analogs had longer lifetimes than the wild-type SRIF molecule. To this end, we determined the  
half-life of the new molecules in human serum and compared them with the values obtained for SRIF, 
[D-Trp]-SRIF and octreotide. The results of this are shown in Table 2. Peptidic analogs 1–3, containing 
only one Msa residue, showed low serum stabilities. Among them, only analogue 2 was more stable 
than SRIF. However, analogs containing the double modification of one Msa residue and D-Trp8 (4–6) 
showed a remarkable increase in stability (7 to 20-fold larger than SRIF). Peptides with two Msa 
residues (compounds 7, 9) also showed higher stability than SRIF, with peptide 7 having a half-life of 
43.9 h (versus 2.75 h of SRIF). Analog 10, with three Msa residues in its sequence, showed the highest 
serum stability (34 times more stable than the natural hormone) although, as we will discuss below, 
this peptide has no affinity toward any of the somatostatin receptors. In summary, the incorporation of 
non-natural amino acids results in enhanced serum stability for the majority of analogs. The effect of 
only one residue is relatively small but replacing two or three residues with non-natural amino acids in 
the somatostatin scaffold increases the overall stability up to 30-fold. Although this value is still far 
from the stability of octreotide (200 h in serum), the increase from hours to days constitutes a 
significant improvement. 
2.3. Binding Activity 
The receptor subtype selectivity was measured using competition-binding assays in Chinese 
hamster ovary (CHO) cell lines. For comparative purposes, the same tests were applied to SRIF-14,  
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[D-Trp8]-SRIF and octreotide. In short, stable CHO cell lines that specifically express each of the five 
SSTR receptors were cultured and centrifuged to extract the membranes. Inhibitor selectivity was 
determined with a competitive assay using 125I-labeled and unlabeled SRIF-14 in all five receptors. All 
binding data is shown in Table 2. As can be readily seen, the new peptides show a wide scope of 
biological activities, ranging from moderately active in all receptors (compound 1), to remarkably 
selective (compounds 2–5) or even completely inactive (compound 10). These affinity values will be 
discussed below in more detail in parallel with their structures. 
Table 2. Ki values (nM) to receptors SSTR1-5 of peptides 1–10, SRIF, [D-Trp8]-SRIF  
and octreotide. 
Peptide SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 t1/2 (h) a 
Somatostatin, SRIF 0.43 ± 0.08 0.0016 ± 0.0005 0.53 ± 0.21 0.74 ± 0.07 0.23 ± 0.04 2.75 
[D-Trp8]-SRIF 0.32 ± 0.11 0.001 ± 0.0007 0.61 ± 0.02 5.83 ± 0.44 0.46 ± 0.24 19.7 
Octreotide 300 ± 85 0.053 ± 0.011 15.2 ± 5.9 >103 11.53 ± 1.91 200 
[L-Msa6]-SRIF, 1 8.52 ± 1.45 1.49 ± 1.45 1.36 ± 1.45 3.62 ± 1.45 0.91 ± 1.45 2.1 
[L-Msa7]-SRIF, 2 c 4.17 ± 1.45 0.019 ± 0.009 >103 28.72 ± 6.9 >103 5.2 
[L-Msa11]-SRIF, 3 19.97 ± 5.26 0.024 ± 0.004 2.8 ± 0.22 6.45 ± 2.23 2.1 ± 0.70 1.7 
[L-Msa6_D-Trp8]-SRIF, 4 c 3.08 ± 0.9 4.55 ± 0.66 0.78 ± 0.1 4.70 ± 0.92 0.36 ± 0.003 26 
[L-Msa7_D-Trp8]-SRIF, 5 c 0.33 ± 0.09 0.0024 ± 0.001 7.49 ± 0.63 >103 >103 25 
[L-Msa11_D-Trp8]-SRIF, 6 c 3.35 ± 1.32 0.14 ± 0.06 1.31 ± 0.2 >103 0.73 ± 0.19 41 
[L-Msa6,7]-SRIF, 7 >103 14.69 ± 0.82 >103 >103 >103 43.9 
[L-Msa6,11]-SRIF, 8 >103 >103 13.34 ± 2.92 >103 9.12 ± 0.61 nm b 
[L-Msa7,11]-SRIF, 9 105.75 ± 30.6 1.37 ± 0.32 >103 >103 >103 10 
[L-Msa6,7,11]-SRIF, 10 >103 >103 >103 >103 >103 93.3 
Ki values are mean ± SEM. Shaded cells represent data in close proximity to the SRIF values. a Human serum 
half-life. b Not measured. c Described in the preliminary communication [21]. 
2.4. NMR Structure 
2.4.1. Compounds 1–3 with One Msa Residue 
The SRIF analogs containing only one Msa insertion (in position 6, 7 or 11, analogs 1–3) were 
analyzed by NMR. Unlike somatostatin, which populates several conformations in aqueous solution, 
the two dimensional TOCSY and NOESY homonuclear experiments [45] showed a major set of NOE 
peaks. The well-defined 2D spectra of compounds 1–3 enabled us to characterize their main 
conformation in solution using the software Crystallography & NMR System (CNS) [46]. To generate 
the list of experimental restraints required for the calculation, the volume of all assigned peaks was 
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integrated, and then converted into distances. Three calculations (120 structures each) were run until 
the best match between the NMR assignments and final structures was obtained. Based on these  
results we concluded that under the experimental conditions used, compounds 1–3 were sufficiently 
structured to obtain defined families of structures that are in good agreement with the experimental 
data (Figures 4–6). 
Figure 4. Structures of the lowest energy conformers of [L-Msa6]-SRIF (1) (A),  
[L-Msa7]-SRIF (2) (B) and [L-Msa11]-SRIF (3) (C). Hydrogen atoms have been omitted 
for clarity. 
 
The 3D structure of [L-Msa6]-SRIF (1) showed a singular aromatic ring cluster among Msa6, Phe7 
and Phe11 as well as a hairpin (Figure 4A). This arrangement of aromatic rings was defined by a 
number of NOE’s among the aromatic protons of these three residues. However, the absence of an 
additional stabilizing effect in the hairpin area increased the conformational mobility of this peptide. 
Thus, our NMR data suggested that other minor conformations were present in solution. As shown  
in Table 2, compound 1 binds to all receptors although with weaker affinity than somatostatin. 
Furthermore, the presence of only one unnatural residue in its sequence did not increase its stability in 
serum; its half-life is slightly lower than that of the natural hormone. 
The NMR data of [L-Msa7]-SRIF (2) clearly showed that this compound was conformationally 
more rigid than 1 in solution. The 3D structure of the lower energy conformers showed a highly 
structured region from residues 6 to 11, with a clear aromatic interaction between Phe6 and Phe11 
(Figure 4B) which can be defined as an edge-to-face interaction. The Msa residue in the seventh 
position does not participate in the aromatic interaction, lying flat at the opposite face of the molecule. 
However, it probably plays an essential role in conformer stabilization, helping the aromatic rings of 
Phe6 and Phe11 to attain the optimal geometry. NOE crosspeaks of Lys9-Trp8 interaction were weak 
and difficult to identify. Peptide 2 was highly selective towards receptor SSTR2, with a Ki of 0.019 nM. 
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Interestingly, and perhaps due to its conformational stability, the stability of peptide 2 in serum (5.2 h) 
is almost double to that of SRIF, and has the highest stability of the three analogs 1–3 with only one 
residue modification. 
Figure 5. NOESY (600 MHz, D2O, 200 ms) of the aromatic ring-long range interaction 
region of the natural hormone, [D-Trp8]-SRIF, [L-Msa7]-SRIF (2) and [L-Msa7,D-Trp8]-
SRIF (5). NMR data were acquired at 285 K, using trifluoroacetate as a counter-ion at pH 1.5. 
 
The set of low energy conformers calculated for peptide [L-Msa11]-SRIF (3) showed a remarkable 
level of convergence in the majority of geometrical parameters as a result of the high number of 
experimental restraints observed and the intrinsically high conformational rigidity in the molecule. In 
this analog, the Msa amino acid at position 11 participates in a π-π aromatic interaction, with the 
phenyl ring of Phe6 oriented in an offset-tilted arrangement on one side of the molecular plane  
(Figure 4C). Moreover, the Phe7 ring lies on the other side of the molecular plane as it occurs in the 
structure of molecule 2, but in 3 the orientation is almost perpendicular to the plane. 
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Figure 6. Structures of the lowest energy conformers of [L-Msa6,D-Trp8]-SRIF (4) (A), 
[L-Msa7,D-Trp8]-SRIF (5) (B) and [L-Msa11,D-Trp8]-SRIF (6). (C). Hydrogen atoms have 
been omitted for clarity. 
 
As observed in peptide 2, the interaction between the side chains of Lys9 and Trp8 is instrumental 
in defining the formation of the hairpin. However, these interactions are not strong enough to fix the  
L-Trp8 in a fixed rotamer, with some conformations of peptide 3 bringing the L-Trp8 indole side-chain 
in close proximity to the benzyl side-chain of Phe7. Remarkably, the binding profile of this compound 
reflects that it is highly selective toward SSTR2, despite having a dissociation constant larger than that 
of compound 2. However, its stability in serum is poor, displaying a half-life even shorter than that of 
natural SRIF. 
2.4.2. Compounds 4–6 with One Msa Residue and D-Trp8 
The discovery of unique conformations in peptides 1–3, which allowed us to determine their 3D 
structures by NMR in aqueous solution, prompted us to concentrate our efforts on increasing the 
stability of these analogs while maintaining their binding properties. Pioneering work by Rivier and 
co-workers in 1975 [39] showed that [D-Trp8]-SRIF exhibits an excellent binding profile toward all 
receptors but higher stability than its [L-Trp8]-SRIF natural counterpart. Indeed, several studies [39,40] 
have demonstrated that the Lys9 side chain is more effectively shielded by [D-Trp8] because the  
D-configuration of tryptophan favors an orientation where the indole ring is in close proximity to the 
aliphatic side chain of Lys9. These contacts not only maintain the Lys9 side chain in a defined 
orientation, but also induce the formation of the hairpin centered at Trp8-Lys9. 
Our aim was to investigate whether the introduction of the [D-Trp8] residue would increase the 
stability of the peptides containing Msa side-chains while maintaining the conformational structure and 
the binding profile. Therefore, we prepared three new analogs 4–6 carrying Msa and [D-Trp8] residues 
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by SPPS and determined whether these substitutions affected either the structure or stability of the 
peptides. In addition, we also prepared the [D-Trp8]-SRIF analog and compared its NMR properties 
with that of the natural [L-Trp8]-SRIF. A section of the 2D NOESY spectra of the natural hormone, 
[D-Trp8]-SRIF, [L-Msa7]-SRIF (2) and [L-Msa7,D-Trp8]-SRIF (5), is shown in Figure 5 to illustrate 
the improvement in the NMR data. As it can be observed, [D-Trp8]-SRIF maintains the intrinsic 
flexibility of the natural hormone, whereas 2 and 5 show an increasing amount of NOE signals. 
The conformational flexibility of both SRIF and [D-Trp8]-SRIF accounts perfectly for its functional 
versatility against all receptors (SSTR1-5) (Table 2). In both cases, the coexistence of several different 
conformations prevented us from carrying out definitive structural studies. In contrast, the 2D spectra 
of compounds 4–6 were extremely well-defined, enabling us to characterize their main conformation 
in solution from the NMR restraints and using the CNS software. As before, the volume of all assigned 
peaks was integrated, transformed into distances and used to generate the list of experimental restraints 
for calculation. Three sets of calculations (120 structures each) were run until the best match between 
assignments and final structures was obtained. As expected, the generated structures (from the 
experimental NMR data) of these new peptides showed a clear increase in convergence not only with 
respect to SRIF and [D-Trp8]-SRIF, but also with respect to monosubstituted analogs 1–3. 
Peptide [L-Msa6,D-Trp8]-SRIF (4) gave a well-defined conformation in solution (Figure 6A) in 
which the two aromatic rings of Msa6 and Phe11 are markedly proximal due to the enhanced aromatic 
interaction, while Phe7 is also participating in the aromatic cluster. This cluster of three aromatic rings 
is similar to the one found in [L-Msa6]-SRIF (1). It is apparent that the region containing residues 5–11 
is much more structured than the rest of the molecule. The pharmacophore region of the most stable 
conformations matched perfectly (residues 6 to 11). On the other hand, the rest of the molecule is less 
rigid. The binding profile of peptide 4 is also similar to peptide 1, although its affinity towards 
receptors SSTR3 and SSTR5 is comparable to that of the natural hormone, with an affinity 20–30 times 
more potent than octreotide (Table 2). The lack of affinity of both peptides 1 and 4 towards receptor 
SSTR2 (which both have a Msa residue in the sixth position) does not support the idea that residue 6 
interacts via a π-donation with an amino acid side chain in SSTR2, as suggested in Hirschmann’s 
hypothesis [47]. 
Peptide [L-Msa7,D-Trp8]-SRIF (5) also showed a strong interaction between Phe6-Phe11 and a 
well-defined hairpin at the pharmacophore region (Figure 6B). This hairpin was also observed in the 
[L-Msa7]-SRIF peptide (2). Again, the calculated structures display a good degree of convergence, 
being the pharmacophore region (residues 5–11) more structured than the remaining part of the 
molecule. In contrast to peptide 2, a large set of interactions between Trp8 and Lys9 can be clearly 
observed in compound 5. In this case, the Lys-Trp interaction is reflected in the upfield shift γ protons 
of Lys9 which are shielded by the aromatic indole ring. Furthermore, the aromatic-aromatic 
interactions between residues Phe6 and Phe11 in peptides 2 and 5 are very similar as depicted in 
Figure 7, (the backbone is shown as a cartoon representation and the Phe6 and Phe11 residues as 
sticks). The molecules were rotated with respect to previous figures to provide a close view of these 
interactions. The aromatic pair association can be classified as an edge-to-face type [48,49]. The 
shortest inter-residue carbon-carbon distances (SICD) are 3.3 and 2.7 Å respectively. The angle 
formed between the ring centroid to centroid segment and the z-axis of an axial system centered on the 
centroid of the reference ring (θ) is very small (16° and 13° for 2 and 5 respectively). The ring planes 
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are almost perpendicular with interplanar angles (P) of 81° and 72° respectively. The mesityl ring in 
peptide 5, as in peptide 2, is not involved in any aromatic interactions. The aromatic ring is lying flat at 
the other side of the molecule, probably facilitating the interaction between both Phe6 and Phe11 by 
steric repulsion. The lowest energy conformation is fairly similar to 2, but the synergistic stabilizing 
effect due to the presence of the D-Trp8 leads to the least flexible 14-residue SRIF analogue described 
to date. Its outstanding affinity for SSTR2 probably correlates with having a well-defined structure 
close to the conformation that fits best in the structure of the SSTR2 receptor, which is so far 
uncharacterized. Its inhibition constant was 22-fold lower than that of octreotide and similar to SRIF. 
Peptide 5, unlike octreotide, also exhibited an impressive affinity toward SSTR1, at the same level 
than SRIF. 
Figure 7. Schematic representation of the aromatic interactions in peptides 2, 3, 5 and 6. 
 
The analogue [L-Msa11,D-Trp8]-SRIF (6) also had remarkable conformational stability. The most 
stable conformers showed a strong π-π aromatic interaction between the Phe6 and Msa11 residues as 
displayed in Figure 6C. It was also apparent that peptides 3 and 6 showed a remarkable similarity  
to one another. The geometric values of the aromatic interaction in peptides 3 and 6 are shown in 
Figure 7 showing only the backbone and the two aromatic rings of the most stable conformer. In this 
case, the position of the two aromatic rings fits as an offset-tilted interaction, with the θ angles wider 
than in previous analogs (30° and 34° for 3 and 6 respectively). In this case, the interplanar angles (P) 
are 53° and 61° (Figure 7). Peptide 6 showed high affinity towards the SSTR5 receptor, although it 
displayed a lower level of selectivity, since it also binds to SSTR1, SSTR2 and SSTR3 receptors with 
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comparable affinities. Its stability in serum is very high (41 h), which is higher than any of the analogs 
prepared carrying one Msa and the D-Trp8 residues. 
Overall, the structures of peptides with L-Trp8 (compounds 1–3) are remarkably similar to those 
with D-Trp8 (compounds 4–6). Nearly all of the observed NOE’s for compounds 1–3 were also present 
in the spectra of compounds 4–6. This suggests that in peptides 4–6, the D-Trp8 residue shifts the 
equilibrium toward conformations that are already populated in a considerable manner in peptides 1–3. 
The NMR data of compounds 4–6 showed a higher increase in number and intensity of the contacts 
between Trp8-Lys9 than peptides 1–3. Furthermore, the contrast between the γ protons of Lys9 in peptides 
1–3 (which showed a similar shift to those in [L-Trp8] SRIF), and analogs 4–6 (which were significantly 
upfield shifted) could be attributed to the efficient interaction of the Lys9 and D-Trp8 side chains. 
2.4.3. Compounds 7–10 with Multiple Incorporations of Msa Residues 
Since a simple substitution of Phe by Msa in the natural sequence remarkably increased the 
conformational rigidity of the analogs, we went a step further and studied whether the addition of 
multiple Msa residues could have an impact on their structure and/or their interaction with the 
receptors. To obtain this information, we prepared peptides 7–10 (Table 1) using the general SPPS 
methods. Analogs 7–10 showed a minimal number of NOE signals (mainly sequential NOE’s could be 
assigned), proving that the presence of more than one Msa in the 14-amino acid sequence does not 
improve the conformational stability of these SRIF derivatives in solution. A probable explanation for 
this negative effect on the fold of the peptide can be rationalized based on the large steric hindrance 
imposed by the ortho- methyls of Msa residues, preventing the aromatic interaction between Msa 
residues. This explanation is supported by the lack of NOEs between the aromatic mesityl protons. It 
appears that the 14-residue-sequence of somatostatin would accommodate more than one Msa in 
positions 6, 7 and/or 11, but this is at the price of losing the structural properties of the native hormone. 
Most importantly, the presence of several Msa residues reduces the affinity of the peptides towards the 
five SSTR receptors. In particular, compound 10, containing three Msa residues, was completely 
inactive towards all of the SSTR receptors (Table 2). 
3. Experimental 
3.1. General Syntheses of Peptides 
The syntheses were performed by SPPS on a 2-Cl-Trt resin (1.60 mmol/g) using the Fmoc/tBu 
strategy. Initially, the first amino acid Fmoc-L-Cys(Trt)-OH (1 equiv) was coupled in the presence of 
DIPEA (4 equiv) in DCM as solvent for 40 min and finally end-capped with methanol (0.8 mL g−1).  
Then, Fmoc removal was performed by treating the peptidyl resin with 20% piperidine in DMF (1 × 1’ and 
1 × 5’). The second amino acid Fmoc-L-Ser(tBu)-OH (2.5 equiv) was coupled using DIC (2.5 equiv) 
and HOBt (2.5 equiv), as activating reagents, in DMF for 40–60 min. Kaiser test was used to check 
coupling completions [50]. This procedure was repeated for the following eleven Fmoc-protected amino 
acids and for the last Boc-L-Ala-OH. When Fmoc-L-Msa-OH was coupled, only 1.5 equiv were used. 
The cleavage of the fully protected linear peptide from the resin was carried out using a 
DCM/TFE/AcOH mixture for 2 h. The formation of the disulfide bridge in all the analogs was 
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achieved using iodine at room temperature and then quenched with an aqueous solution of sodium 
thiosulphate 1N. The aqueous layer was extracted with DCM (3 × 4 mL), the combined organic layer 
was washed with a mixture of an aqueous citric acid 5% solution/sodium chloride (1:1) and evaporated 
under reduced pressure. Finally, total deprotection of the side-chains was performed using an  
acidic mixture (TFA/DCM/anisole/H2O 12/6/2/1). Then, the remaining solution was washed with 
heptane (20 mL) and the aqueous layer was precipitated in Et2O (−10 °C) afforded somatostatin 
analogs. Analogue [D-Trp8]-SRIF, used for receptor binding assays and NMR data comparison, was 
synthesized following this general procedure by incorporating Fmoc-D-Trp-OH instead of the natural 
enantiomer. Analytical and preparative HPLC were carried out with C8 Kromasil columns using 
gradients of solvent A (0.1% TFA in H2O) and solvent B (0.07% TFA in CH3CN). Yields of peptides 
are based in re-calculated loading of the resin. 
[L-Msa6]-SRIF (1): Somatostatin analogue 1 was synthesized following the general procedure from 
0.136 g of 2-Cl-Trt resin (1.60 mmol/g) and using Fmoc-L-Msa-OH, affording 0.20 g of 7 in 60% 
yield (95% purity after purification). HPLC: tR = 14.3 [Gradient 25%–60%B in 20 min, flux: 1 mL 
min−1, λ = 220 nm]. HRMS: calcd for 1678.8; found, 1680.2. 
[L-Msa7]-SRIF (2), [L-Msa6,D-Trp8-SRIF] (4), [L-Msa7,D-Trp8-SRIF] (5) and [L-Msa11, 
D-Trp8]-SRIF (6) were synthetized according to ref. [21]. 
[L-Msa11]-SRIF (3): Somatostatin analogue 3 was synthesized following the general procedure from 
0.136 g of 2-Cl-Trt resin (1.60 mmol/g) and using Fmoc-L-Msa-OH, affording 0.28 g of 9 in 44% 
yield (99% purity after purification). HPLC: tR = 14.1 [Gradient 25%–60%B in 20 min, flux:  
1 mL min−1, λ = 220 nm]. HRMS: calcd for 1678.8; found, 1680.0. 
[L-Msa6,7]-SRIF (7): Somatostatin analogue 7 was synthesized following the general procedure from 
0.10 g of 2-Cl-Trt resin (1.60 mmol/g) and using Fmoc-L-Msa-OH, affording 0.12 g of 10 in 20% 
yield (98% purity after purification). HPLC: tR = 16.5 [Gradient 25%–60%B in 20 min, flux:  
1 mL min−1, λ = 220 nm]. HRMS: calcd for 1721.1; found, 1721.0. 
[L-Msa6,11]-SRIF (8): Somatostatin analogue 8 was synthesized following the general procedure from 
0.136 g of 2-Cl-Trt resin (1.60 mmol/g) and using Fmoc-L-Msa-OH, affording 0.28 g of 11 in 44% 
yield (99% purity after purification). HPLC: tR = 15.4 [Gradient 25%–60%B in 20 min, flux:  
1 mL min−1, λ = 220 nm]. HRMS: calcd for 1721.1; found, 1720.8. 
[L-Msa7,11]-SRIF (9): Somatostatin analogue 9 was synthesized following the general procedure from 
0.10 g of 2-Cl-Trt resin (1.60 mmol/g) and using Fmoc-L-Msa-OH, affording 0.13 g of 12 in 44% 
yield (99% purity after purification). HPLC: tR = 16.4 [Gradient 25%–60%B in 20min, flux:  
1 mL min−1, λ = 220 nm]. HRMS: calcd for 1721.1; found, 1721.0. 
[L-Msa6,7,11]-SRIF (10): Somatostatin analogue 10 was synthesized following the general procedure 
from 0.10 g of 2-Cl-Trt resin (1.60 mmol/g) and using Fmoc-L-Msa-OH, affording 0.10 g of 13 in  
44% yield (95% purity after purification). HPLC: tR = 18.4 [Gradient 25%–60%B in 20 min, flux:  
1 mL min−1, λ = 220 nm]. HRMS: calcd for 1762.9; found, 1763.2. 
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3.2. NMR and Computational Methods 
NMR experiments were recorded in H2O/D2O (90/10) without buffer. The resulting solutions had a 
pH of 1.5–2. The concentration was 5 mM aprox. (4 mg in 0.5 mL). 2D TOCSY and NOESY 
homonuclear experiments were acquired in a Bruker Avance III spectrometer (600 MHz). Chemical 
shifts are recorded in ppm. All NMR data was processed with NMRPipe [51] Cara [52] was used to 
assign the spectra. Distance restraints derived from fully assigned peaks in NOESY experiments were 
used for structure calculation. The structures were calculated with the programs CNS [46] and 
StructCalc (StructCalc program was used by courtesy of its recent developers: Pau Martín-Malpartida 
and Maria J. Macias; unpublished data). Statistics from the analyses are shown in Supporting 
Information. PyMOL was used to visualize the structures and generate the figures. 
3.3. Preparation of Cells Stably Expressing the SRIF-14 Receptor 
CHO-K1 cells (American Type Culture Collection, Rockville, MD, USA) were maintained in 
Kaighn’s modification of Ham’s F12 medium (F12K) supplemented with 10% fetal bovine serum. 
pcDNA3 vectors encoding each of the SSTR receptors were obtained from UMR cDNA Resource 
Center (University of Missouri, Columbia, MO, USA). CHO-K1 cells were stably transfected with 
these vectors by using Lipofectamine (Life Tecnologies Corporation, 5791 Van Allen Way, Carlsbad, 
CA, USA). Stable clones were selected in F12K containing G418 (700 µg/mL) and were screened for 
SRIF-14 receptor expression and then maintained in a G418 (400 µg/mL)-containing medium. 
Expression was detected by RT-PCR and western-blot and confirmed by radio ligand binding assays. 
3.4. Receptor Ligand-Binding Assay 
All receptor-binding assays were performed with membranes isolated from CHO-K1 cells 
expressing the cloned human SRIF-14 receptor, as reported previously [53]. The assay buffer consisted 
of 50 mM Tris (pH 7.5) with 1 nM EGTA, 5 mM MgCl2, leupeptin (10 µg/mL), pepstatin (10 µg/mL), 
bacitracin (200 µg/mL), aprotinin (0.5 µg/mL) and 0.2% BSA. CHO-K1 cell membranes, radiolabeled 
SRIF-14 and unlabeled test compounds were diluted in this assay buffer. All assays were performed in 
96-well polypropylene plates. Ten micrograms of membrane proteins were incubated with 0.1 nM of 
125I-Tyr11-SRIF (specific activity 2,000 Ci/mmol) in the presence or absence of various concentrations 
of unlabeled peptides (1 pM–1,000 nM) in a total volume of 200 µL, for 1 h at 30 °C. The binding reaction 
was terminated by vacuum filtration over Whatman GF/F glass fibre filters previously pre-soaked in  
0.5% (w/v) polyethyleneimine and 0.2% bovine serum albumin, using a 98-well harvester (Inotech 
Biosystems International Inc.,  Dietikon,  Switzerland). The filters were washed with ice-cold 50 mM 
Tris-HCl (pH 7.5) and dried, after which scintillator sheets were melted onto the filter and the bound 
radioactivity was analyzed in a liquid scintillation counter (microβ plus, PerkinElmer, Wallac, Waltham 
Massachusetts USA). Specific binding was defined as the total 125I-Tyr11-SRIF binding minus the 
amount bound in the presence of 1,000 nM SRIF (non-specific binding). Inhibition curves were 
analyzed and IC50 values were calculated using a curve-fitting program (GraphPad Prism, La Jolla, 
CA, USA). The Ki values for the compounds were determined as described by Cheng and Prusoff [54]. 
Data are the mean ± S.E.M. of at least three separate experiments, each performed in triplicate. 
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3.5. Serum Stability Assay 
A peptide solution of 6 mg/mL in water (1.8 mg in 300 µL) was sterilized by filtration (0.22 µm 
filter). Aliquots from this solution (10 µL) were added to 90 µL of serum (from human male AB 
plasma, sterile filtered; Sigma-Aldrich, Inc., St. Louis, MO, USA). These solutions were incubated at 
35 °C and samples were taken at 0 min, 1 h, 7 h, 17 h, 24 h and 48 h. Each sample was treated with 
acetonitrile (200 µL) and cooled to 0 °C for 30 min to precipitate the proteins. The suspensions were 
centrifuged at 10,000 rpm, during 10 min at 4 °C. The process was repeated twice. The solution  
was filtered through 0.45 µm of PVDF. The samples were analyzed by HPLC; eluent: 20%–80% B  
(B = 0.07% TFA in acetonitrile); 20 min gradient; flow: 1 mL min−1. For each peptide the experiment 
was repeated twice. Cleavage of the Ala1-Gly2 moiety was not considered as peptide deterioration. 
The half-life of the peptide in serum was calculated from the analysis of these degradation data. The 
concentration of the peptide was taken from the chromatogram integration. 
4. Conclusions 
We have synthesized and studied ten new somatostatin analogs (Table 1) that can be grouped as 
follows: (a) introduction of one Msa residue in positions 6, 7 or 11 of the natural 14 amino acid 
sequence (peptides 1–3); (b) the same as in (a) but replacing natural L-Trp with D-Trp at position 8 
(peptides 4–6); and (c) multiple incorporations of Msa in positions 6, 7 and 11 (peptides 7–10). All 
analogs were tested for their ability to bind to the SSTR receptors, for their stability in serum (Table 2) 
and were studied in detail by NMR. 
The presence of favorable defined conformations in peptides 1–6 allowed us to characterize their 
structure in detail by computational techniques using NMR restraints. Analogs containing one Msa and 
D-Trp are more structured than those with the natural amino acids although the most stable set of 
conformers did not appear to change significantly with the replacement of L-Trp with D-Trp 
(comparing compounds 1 to 4, 2 to 5 and 3 to 6). The increase of conformational rigidity stems from 
the reinforcement of aromatic interaction between certain residues when Msa is present, and the 
preferred interaction of the indole ring with the lysine side chain when the Trp8 residue has a  
D configuration. It is known that Lys9 is more effectively shielded by Trp8 when Trp8 has a  
D configuration due to the closer proximity between the indole group of Trp and the aliphatic side 
chain of Lys9. The single modification of introducing one Msa residue combined with the presence of  
D-Trp8 enhanced what were before weak interactions among the aromatic side-chains in SRIF, leading to 
analogs with greater stability which possessed higher affinities and selectivity towards the SSTR receptors. 
It is worth noting that the majority of the contacts present in the NOESY spectra of these 
compounds were also detected in the parent compound, indicating that these Msa containing analogs 
preferentially populates a dominant conformation that already exists in solution in somatostatin. In all 
cases (compounds 1–6) we have found that non-covalent aromatic interactions occur between residues 
in sixth and eleventh position. Therefore our results are consistent with the hypothesis described by 
Veber and co-workers [12] that an aromatic interaction between Phe6 and Phe11 stabilizes the 
bioactive conformation to a certain degree in SRIF. Analogs 2 and 5 satisfy both high conformational 
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rigidity and an excellent SSTR2 selectivity; consequently, the 3D structure of these 14-aa SRIF 
analogs should be close to that of SRIF binding receptor SSTR2. 
The structures of peptides with L-Trp8 (compounds 1–3) are remarkably similar to those with  
D-Trp8 (compounds 4–6). It appears that the configuration of this amino acid does not play a 
fundamental role in the architecture of the peptide. However, the presence of D-Trp8 proved to be 
important not only in hairpin stabilization, but also to increase the serum stability. This could be due to 
the increased stability to proteases of peptides with D-residues and also to the increased overall 
conformational stability of the peptide. The combined presence of both Msa and D-Trp8 (compounds 4–6) 
could be a synergistic effect and explains the higher serum stability of peptides 4–6 than [D-Trp8]-SRIF or 
compounds 1–3. The enrichment of non-covalent interactions (stabilization of the hairpin area due to the 
presence of D-Trp8 and intensification of the aromatic-aromatic interactions due to the Msa) explains their 
higher serum stability in comparison to SRIF. However, peptides 7–10 with two or three Msa residues, 
although possessing a longer half-life in serum, do not show any defined structure in solution (their 3D 
structure could not be determined) and have poor affinities towards the majority of SSTR receptors. 
The potential therapeutic utility of SSTR-selective ligands has been extensively reported [9–12]. In 
the past decade, the somatostatin-based receptor-targeted anti-cancer therapy has emerged as a 
promising tool in order to improve the traditional chemotherapy [55,56]. Precisely, SSTR2 is 
expressed at remarkably higher levels in many tumor cells relative to normal tissues. The coupling of 
potent chemotherapeutic agents to SSTR2-selective somatostatin analogs has provided new cytotoxic 
SRIF-conjugates that selectively target SSTR2-specific sites, displaying significant anti-tumor abilities 
in many different types of tumors [57,58]. Due to the short half-life of full length somatostatin analogs, 
only octreotide derivatives are currently used in SSTR-targeted chemotherapy. In this regard, an array 
of additional investigations of the use of peptide 5 (10 times more stable in serum than SRIF and  
10-fold more active against SSTR2 than octreotide) in receptor-targeted anti-cancer therapy is 
currently underway in our laboratory. 
In summary, the replacement of Phe residues by Msa in the original somatostatin sequences has 
allowed us to fine-tune the structural and biological properties of the corresponding peptide analogs, 
facilitating deeper insights to the main factors that control the conformation and receptor selectivity of 
this important hormone. 
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